Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine

计划入组 420 人 · 首次发布于 2014 年 1 月 17 日

Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

计划入组 4,748 人 · 首次发布于 2016 年 1 月 29 日

Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies

计划入组 44 人 · 首次发布于 2015 年 6 月 16 日

Norovirus GI.4/GII.4 Bivalent VLP Vaccine (Icon Genetics GmbH)

Norovirus GI.1/GII.4 Bivalent Virus-like Particle(Takeda)

GI Innovation, Inc.

South Korea

GI NUTRIHEALTH PTY LTD

Australia

MOTUS GI MEDICAL TECHNOLOGIES LTD

Israel

Airplane Wastewater Surveillance Detects SARS-CoV-2 Variants Weeks Before Clinical Systems

Vaxart Advances Second-Generation Norovirus Oral Vaccine with Improved Immune Response Data

Norovirus Vaccine Development Advances with mRNA and Oral Tablet Candidates